INLEZIFIGENE CIVAPARVOVEC
UNII 87RN2MR2FP

Substance Identification & Data

This profile provides standardized clinical and technical data for Inlezifigene Civaparvovec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 87RN2MR2FP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2143578-31-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
87RN2MR2FP
CAS Registry Number
2143578-31-6
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
INLEZIFIGENE CIVAPARVOVEC
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
10977
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Inlezifigene Civaparvovec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

INLEZIFIGENE CIVAPARVOVEC

Common Names & Synonyms

INLEZIFIGENE CIVAPARVOVEC [INN]

Systematic Nomenclature

A RECOMBINANT NON-REPLICATING ADENO-ASSOCIATED VIRUS TYPE 2/6 (RAAV REP2-CAP6) VECTOR, EXPRESSING A CDNA THAT TARGETS 447-461 BP OF THE ALBUMIN LOCUS (RELATIVE TO THE TRANSCRIPTION INITIATION SITE), FUSED TO THE OBLIGATE HETERODIMERIC FOKI NUCLEASE DOMAIN ELD, UNDER THE CONTROL OF AN APOLIPOPROTEIN E HEPATIC CONTROL REGION AND HUMAN ALPHA-1-ANTITRYPSIN PROMOTER (APOE/HAAT)